A detailed history of Teza Capital Management LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Teza Capital Management LLC holds 15,589 shares of PCRX stock, worth $258,777. This represents 0.03% of its overall portfolio holdings.

Number of Shares
15,589
Previous 13,214 17.97%
Holding current value
$258,777
Previous $378,000 38.1%
% of portfolio
0.03%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $28.46 $27,787 - $67,592
2,375 Added 17.97%
15,589 $234,000
Q2 2024

Aug 14, 2024

SELL
$25.5 - $31.51 $146,395 - $180,898
-5,741 Reduced 30.29%
13,214 $378,000
Q1 2024

May 15, 2024

BUY
$27.7 - $35.48 $293,509 - $375,946
10,596 Added 126.76%
18,955 $553,000
Q4 2023

Feb 14, 2024

SELL
$26.32 - $34.31 $292,573 - $381,389
-11,116 Reduced 57.08%
8,359 $282,000
Q3 2023

Feb 22, 2024

BUY
$30.68 - $40.09 $26,323 - $34,397
858 Added 8.9%
10,499 $322,000
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $116,798 - $152,622
3,807 Added 24.3%
19,475 $597,000
Q2 2023

Feb 22, 2024

BUY
$36.12 - $47.5 $46,305 - $60,895
1,282 Added 15.34%
9,641 $386,000
Q2 2023

Aug 14, 2023

BUY
$36.12 - $47.5 $565,928 - $744,230
15,668 New
15,668 $627,000
Q3 2020

Nov 12, 2020

SELL
$51.97 - $63.0 $417,163 - $505,701
-8,027 Closed
0 $0
Q2 2020

Aug 10, 2020

BUY
$30.8 - $52.47 $247,231 - $421,176
8,027 New
8,027 $421,000
Q4 2018

Feb 14, 2019

SELL
$41.31 - $52.16 $271,117 - $342,326
-6,563 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$32.85 - $52.0 $215,594 - $341,276
6,563 New
6,563 $323,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $761M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Teza Capital Management LLC Portfolio

Follow Teza Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Teza Capital Management LLC with notifications on news.